Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Classificação em ações #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Preço da ação
$265.95
Valor de mercado
$469.88B
Variação (1 dia)
0.34%
Variação (1 ano)
19.48%
País
US
Negociar AbbVie Inc. (ABBV)

Categoria

Margem Operacional de AbbVie Inc. (ABBV)
Margem Operacional em September 2026 TTM: 29.32%
De acordo com os relatórios financeiros mais recentes e o preço das ações da AbbVie Inc., a margem operacional atual (TTM) é 29.32%. No final de 2024, a margem operacional era 16.22%.
Histórico da Margem Operacional da AbbVie Inc. de 2009 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
2026 (TTM) 29.32% -15.48%
2025 34.69% 113.87%
2024 16.22% -30.95%
2023 23.49% -24.74%
2022 31.21% -2.13%
2021 31.89% 28.54%
2020 24.81% -36.43%
2019 39.03% 100.26%
2018 19.49% -42.39%
2017 33.83% -7.14%
2016 36.43% 10.49%
2015 32.97% 92.92%
2014 17.09% -43.30%
2013 30.14% -4.77%
2012 31.65% 52.53%
2011 20.75% -31.20%
2010 30.16% -13.08%
2009 34.70% 0.00%
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
43.92% -98.50%
US
26.81% -99.09%
US
26.59% -99.09%
CH
16.65% -99.43%
US
31.24% -98.93%
CH
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.